Filing Details

Accession Number:
0001171843-14-004238
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-09-08 20:33:37
Reporting Period:
2014-09-04
Filing Date:
2014-09-08
Accepted Time:
2014-09-08 20:33:37
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
3116 Akorn Inc AKRX Pharmaceutical Preparations (2834) 720717400
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1277838 M Ronald Johnson 1925 West Field Court Suite 300
Lake Forest IL 60045
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-09-04 50,000 $1.60 131,557 No 4 M Direct
Common Stock Acquisiton 2014-09-04 10,000 $1.60 141,557 No 4 M Direct
Common Stock Acquisiton 2014-09-04 10,000 $1.60 151,557 No 4 M Direct
Common Stock Disposition 2014-09-04 2,947 $38.51 148,610 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options (Right to Buy) Disposition 2014-09-04 50,000 $0.00 50,000 $1.60
Common Stock Stock Options (Right to Buy) Disposition 2014-09-04 10,000 $0.00 10,000 $1.60
Common Stock Stock Options (Right to Buy) Disposition 2014-09-04 10,000 $0.00 10,000 $1.60
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2009-11-19 2014-11-19 No 4 M Direct
0 2009-11-19 2014-11-19 No 4 M Direct
0 2009-11-19 2014-11-19 No 4 M Direct
Footnotes
  1. Proceeds from the sale were used to pay the exercise price of options.
  2. Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $38.50 to $38.56 per share. The reporting person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at separate prices within the foregoing range.
  3. Options fully vested and became exercisable immediately upon grant.
  4. There was no consideration given in exchange for this security.